Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Antonio Salar-Silvestre"'
Autor:
Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, María L. Sánchez-León, Silvia Silva-Romeiro, Rocío Flores-Campos, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Lejeune Marylene, Tomás Álvaro-Naranjo, María Casanova-Espinosa, Antonio Rueda-Domínguez, Víctor Sánchez-Margalet, Luis de la Cruz-Merino
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundDiffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients D
Externí odkaz:
https://doaj.org/article/212d6baeaf2d4c8bb7bf0ab05ba40793
Autor:
Mariano Provencio, Luis de la Cruz-Merino, Delvys Rodriguez-Abreu, Tomás Álvaro, Marylène Lejeune, Carlos Jiménez-Cortegana, Natalia Palazón-Carrión, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Laura Galvez-Carvajal, Margarita Sánchez-Beato, María Guirado-Risueño, Pablo Espejo-García, Victor Sánchez-Margalet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or r
Externí odkaz:
https://doaj.org/article/b89f60e62bf043c59fe379aa70ec66e3
Autor:
Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, Natalia Palazón-Carrión
Supplementary Table from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf9183a00b8270cb46c8800a40d5d32
https://doi.org/10.1158/1078-0432.22487339
https://doi.org/10.1158/1078-0432.22487339
Autor:
Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, Natalia Palazón-Carrión
Purpose:New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma.Patients and Methods:In the phase II R2-GDP trial, 78 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f3c37b5b07b0c28088ac4cb012473f
https://doi.org/10.1158/1078-0432.c.6532499
https://doi.org/10.1158/1078-0432.c.6532499
Autor:
Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, Natalia Palazón-Carrión
Supplementary Data from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e5587b44b63c51aeac3b6410ed474a9
https://doi.org/10.1158/1078-0432.22487342
https://doi.org/10.1158/1078-0432.22487342
Autor:
Juan Jose, Rodríguez-Sevilla, Concepción, Fernández-Rodríguez, Leyre, Bento, Ramón, Diez-Feijóo, Sergio Felipe, Pinzon, Joan, Gibert, Lierni, Fernández-Ibarrondo, Marta, Lafuente, Ana, Ferrer, Blanca, Sanchez-Gonzalez, Eva, Gimeno, Juan, Sainz, Rafael, Ramos-Asensio, Juan F, Garcia, Lluis, Colomo, Beatriz, Bellosillo, Antonio, Gutierrez, Antonio, Salar-Silvestre
Publikováno v:
Blood advances.
Several clinical risk models have been proposed to predict outcome in follicular lymphoma (FL). The development of Next Generation Sequencing (NGS) technologies has allowed the integration of somatic gene mutations in clinical scores to build genotyp
Autor:
Catherine Diefenbach, Won Seog Kim, Chan Cheah, Ajay K. Gopal, Philippe Armand, Ian Flinn, Gareth P. Gregory, Sung-Soo Yoon, Loretta Nastoupil, Jennifer Lue, Vincent Ribrag, Javier Briones, Antonio Salar-Silvestre, Anna Sureda-Balari, Matthew Ku, Hans Cruz, Paul Thaler, Ibrahim Qazi, Rachel Wei, Maya Leabman, Genevive Hernandez, Iris Sison, Elizabeth Budde
Publikováno v:
Cancer Research. 83:CT052-CT052
Background: Recent advances in the treatment of non-Hodgkin lymphoma (NHL) have transformed the landscape and provided significant benefits to patients. Novel agents that target CD19 and CD20 on B cells, such as bispecific T-cell engagers and chimeri
Autor:
Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Daniel J. García-Domínguez, Lourdes Hontecillas-Prieto, Pablo Espejo-García, Isabel Fernández-Román, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Marta Navarro, Lejeune Marylene, Tomás Álvaro-Naranjo, Maria Casanova-Espinosa, Victor Sánchez-Margalet, Antonio Rueda-Domínguez, Luis de la Cruz-Merino
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CLINICAL CANCER RESEARCH
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CLINICAL CANCER RESEARCH
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
Purpose: New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma. Patients and Methods: In the phase II R2-GDP trial, 78 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75a5e119dc106abd893979e1e139f166
http://hdl.handle.net/10230/54477
http://hdl.handle.net/10230/54477
Autor:
Jorge Gomez, Guillermo Rodríguez, Christina Quero Blanco, Natalia Palazón-Carrión, Fatima de la Cruz-Vicente, Delvys Rodriguez-Abreu, Antonio Salar Silvestre, Fernando González, Pablo Espejo García, Antonio Rueda Dominguez, Concepción Nicolás, Eduardo Ríos Herranz, Luis Merino, Josep Guma, M. Guirado, Esteban Nogales Fernández, Mariano Provencio-Pulla, José Gómez-Codina, Natividad Martínez-Banaclocha, Alejandro Martín
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
8019 Background: Lenalidomide is an immunomodulatory drug that could reverse rituximab refractoriness in lymphoma patients (pts). We conducted an open label multicenter phase 2 trial testing the efficacy and toxicity of a combination of lenalidomide
Autor:
Matthias Schwenkglenks, Ruth Pettengell, Corinne Haioun, Francesca Gaia Rossi, Pieternella J. Lugtenburg, Ulrich Duehrsen, B. Pujol, Antonio Salar Silvestre, Tracey Wheeler, Gregor Verhoef
Publikováno v:
Hematology. 18:26-29
IMPACT NHL was a multicenter, observational study in adults with non-Hodgkin lymphoma receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy with or without rituximab. Erythropoietin-stimulating agent treatment was